Rhumbline Advisers Palatin Technologies Inc Transaction History

Rhumbline Advisers

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$0.41 - $0.73 $106,112 - $188,931	-258,810 Closed	0 $0
Q1 2020 May 06, 2020	BUY	$0.36 - $0.79 $1,467 - $3,219	4,075 Added 1.6%	258,810 $110,000
Q4 2019 Feb 05, 2020	SELL	$0.75 - $0.89 $738 - $876	-985 Reduced 0.39%	254,735 $199,000
Q3 2019 Oct 23, 2019	SELL	$0.78 - $1.09 $1,326 - $1,853	-1,700 Reduced 0.66%	255,720 $232,000
Q2 2019 Aug 14, 2019	BUY	$0.98 - $1.64 $11,655 - $19,504	11,893 Added 4.84%	257,420 $299,000

Q1 2019 May 01, 2019	SELL	$0.67 - $1.01 $3,299 - $4,974	-4,925 Reduced 1.97%	245,527 $241,000
Q4 2018 Jan 31, 2019	BUY	$0.63 - $1.0 $51,827 - $82,266	82,266 Added 48.91%	250,452 $177,000
Q3 2018 Nov 07, 2018	SELL	$0.88 - $1.1 $4,060 - $5,075	-4,614 Reduced 2.67%	168,186 $168,000
Q2 2018 Aug 06, 2018	BUY	$0.91 - $1.45 $157,248 - $250,560	172,800 New	172,800 $168,000

3.02K

Ticker PTN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,290,480
Market Cap $16.7M
Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.